Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation

Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation

Abstract Background Mantle cell lymphoma (MCL) is an aggressive and incurable lymphoma. Standard of care for younger patients with MCL is induction chemotherapy followed by autologous stem cell transplantation (auto-HCT). Rituximab maintenance after auto-HCT has been shown to improve progression-fre...

Full description

Bibliographic Details
Main Authors: Robert W. Chen, Joycelynne M. Palmer, Sarah Tomassetti, Leslie L. Popplewell, Jessica Alluin, Pritsana Chomchan, Auayporn P. Nademanee, Tanya Siddiqi, Ni-Chun Tsai, Lu Chen, Fay Zuo, Rosemarie Abary, Ji-lian Cai, Alex F. Herrera, John J. Rossi, Steven T. Rosen, Stephen J. Forman, Larry W. Kwak, Leona A. Holmberg
Format: Article
Language:English
Published: BMC 2018-06-01
Series:Journal of Hematology & Oncology
Subjects:
Bortezomib
Rituximab
CCND1
MRD
Mantle cell lymphoma
Auto-HCT
Online Access:http://link.springer.com/article/10.1186/s13045-018-0631-3

Internet

http://link.springer.com/article/10.1186/s13045-018-0631-3

Similar Items